Call Us: +1 (800) 722-4123 
33
Years in
Business
As of March 31, 2026
*Estimated. Total assets combine both Assets Under Management and Assets Under Advisement for Emerald Advisers, LLC, Emerald Mutual Funds Advisers Trust and Emerald Investment Advisers, LLC. Assets Under Management represent the aggregate fair value of all discretionary and non-discretionary assets, including fee paying and non-fee paying portfolios. Assets Under Advisement represent advisory-only assets where the firm provides a model portfolio and does not have trading authority over the assets.
Biotechnology and Big Pharma’s Imperative for M&A explores the forces reshaping healthcare as large pharmaceutical companies face significant revenue loss from upcoming patent expirations. Drawing on industry data and Emerald’s research, the paper highlights why Small and Mid Cap biotech companies have become critical to innovation—and how a new wave of M&A activity is creating opportunity beneath the surface.
Learn More
While investors have been trying hard to look past the situation in the Middle East, it may get more difficult (and dangerous) to do so … as the U.S. claims it will “guide” ships through the Strait of Hormuz while there are unconfirmed Iranian reports that a U.S. warship was targeted and hit.
Simply put, Emerald manages investment portfolios for our clients. What separates us from other asset management firms is our team and the proprietary research and investment management process.
Learn More
Biotechnology and Big Pharma’s Imperative for M&A explores the forces reshaping healthcare as large pharmaceutical companies face significant revenue loss from upcoming patent expirations.
You are now leaving www.teamemerald.com. Follow the link to learn more about the F/m Emerald Life Sciences Innovation ETF
https://www.emeraldetfs.com/33rd-annual-groundhog-day-exploring-life-sciences-2/ ➜
